Aclarion Presents at the NIH HEAL Initiative Fall Meeting
01. November 2023 08:00 ET
|
Aclarion, Inc.
The Helping to End Addiction Long-term® Initiative, or NIH HEAL Initiative®, is funding ground-breaking low back pain research. The Back Pain Consortium (BACPAC) Research Program, a...
Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver
25. Oktober 2023 08:30 ET
|
Aclarion, Inc.
Porter Hospital Becomes First Facility in Denver to Give Chronic Low Back Pain Patients Access to Revolutionary Nociscan Technology That Measures Biomarkers to Pinpoint the Source of Pain George...
Aclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM Meeting
24. Oktober 2023 08:45 ET
|
Aclarion, Inc.
Nociscan cost-effectiveness abstract poster highlights dominance over provocative discography. The 45th Annual Society for Medical Decision Making (SMDM) Meeting is being held October...
Aclarion Announces Signing Strategic Partnership Letter of Intent With ATEC to Advance Commercialization of Nociscan
23. Oktober 2023 07:00 ET
|
Aclarion, Inc.
Partnership aims to include Aclarion’s Nociscan surgical decisioning technology within ATEC’s AlphaInformatiX platform to better inform spine surgery ATEC is a medical device company dedicated to...
Aclarion Provides Updated Investor Presentation and Corporate Update
02. Oktober 2023 08:00 ET
|
Aclarion, Inc.
Aclarion is steadily executing on a proven path toward standard of care. Ten prominent Key Opinion Leader (KOL) surgeons have formally engaged to partner with the company to drive market traction and...
Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report
25. August 2023 16:10 ET
|
Aclarion, Inc.
BROOMFIELD, CO, Aug. 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging...
Aclarion Announces New Commercial Engagement with The Imaging Center, Grand Rapids, MI
14. Juni 2023 11:27 ET
|
Aclarion, Inc.
BROOMFIELD, CO, June 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging...
Aclarion Announces Statistically Significant Nociscan® Cost-Effectiveness Abstract Presented at ISASS Annual Meeting
08. Juni 2023 07:30 ET
|
Aclarion, Inc.
Nociscan cost-effectiveness abstract highlights dominance over provocative discography and can save the US healthcare system $283M to $441M annually. The International Society for the Advancement...
Aclarion Announces New Engagement with The London Clinic and London Spine Clinic
30. Mai 2023 07:30 ET
|
Aclarion, Inc.
The London Clinic is the UK’s most renowned independent, private hospital, established 1932. The London Spine Clinic is first specialist spinal unit established in England, 1997. The London...
Aclarion’s Key Opinion Leader Program Adds Ninth Surgeon Advisor With Addition of Dean Karahalios, MD
23. Mai 2023 07:30 ET
|
Aclarion, Inc.
Development of This Program Supports Aclarion’s Commitment to Lead With Strong Clinical Evidence and Engage the Payer Community Through Key Opinion Leader Advocacy Aclarion to Participate in...